ERBB2 and breast cancer: The PI3K/AKT/mTOR pathway plays an important role in proliferation, differentiation and survival of cells and has been shown to be associated with resistance to endocrine therapy, human epidermal growth factor receptor 2 (HER2)-directed therapy and cytotoxic therapy in breast cancer [95].